Raloxifene Hydrochloride

• Post Date:

  Aug 26,2015

• Expiry Date:

  Feb 22,2016

• Detailed Description:

  Cas No. :82640-04-8 Quantity: 2000Kilograms
  Specs:USP
  Price:2 USD Kilograms
  Payment Method: T/T, Western Union, MoneyGram,bank transfer
  Tag:Hormone,Keoxifene,Keoxifene Hydrochloride,Evista
  
  Product Name
  Raloxifene Hydrochloride
  
  Synonym
  Raloxifene HCL,Keoxifene,Keoxifene Hydrochloride,
  
  CAS
  82640-04-8
  
  MF
  C28H28ClNO4S
  
  MW
  510.04
  
  Molecular Structure
  
  
  Assay
  99%
  
  Quality Standards
  USP
  
  Appearance
  White crystalline powder
  
  Package
  1kg/Foil bag
  
  
  
  
  Place of Origin
  China
  
  Brand Name
  SMQ
  
  Certification
  ISO9001, ISO14000, KOSHER
  
  Model Number
  82640-04-8
  
  MOQ
  10g
  
  Ref. Price
  USD 1.17/g
  
  Packaging Details
  1kg/bag,100grams/bag, 10grams/bag
  
  Delivery Time
  1-3 days
  
  Payment Terms
  T/T, Western union, Money gram
  
  Supply Ability
  100KGS/week
  
  
  
  
  1. OverView:
  
  Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).
  
  
  
  2. Why is this medication prescribed:
  
  Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods). Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition. Raloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
  
  
  
  

• CAS Registry Number:

  82640-04-8

• Synonyms:

  ;Raloxifene hydrochloride [USAN];6-Hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl ketone, hydrochloride;Evista;Keoxifene hydrochloride;LY 156758;Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, hydrochloride;Raloxifene HCl;UNII-4F86W47BR6;[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]{4-[2-(piperidin-1-yl)ethoxy]phenyl}methanone hydrochloride (1:1);[6-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1-benzothiophen-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone;

• Molecular Formula:

  C₂₈H₂₉NO₄S

• Molecular Weight:

  475.5992

• Molecular Structure:

  

• Company:

  Shenzhen SiMeiQuan Biotechnology Co., Ltd     [ China ]        

• Contact:

  nicole

• Tel:

  86-755-23252301

• Fax:

  86-755-23252301

• Email:

  nicole@chembj.com